Last updated: February 20, 2026
Who are the parties involved?
- Plaintiff: Exelixis, Inc., a biopharmaceutical company specializing in oncology drugs.
- Defendant: Azurity Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on injectable medications.
Case background and allegations
Exelixis filed this lawsuit on January 30, 2025, alleging patent infringement of its U.S. Patent No. 10,789,032, titled "Methods of Treating Cancer with Cabozantinib." The patent covers methods of administering cabozantinib, a tyrosine kinase inhibitor used in cancer therapy.
Exelixis claims Azurity has marketed and sold a generic version of cabozantinib without licensing rights, infringing the patent. The patent is set to expire on May 8, 2030. Exelixis seeks injunctive relief, damages, and an order barring Azurity from further infringing activities.
Azurity disputes the patent’s validity and non-infringement, asserting the patented method is obvious and invalid under 35 U.S.C. § 103. Azurity also challenges the scope of Exelixis’s patent claims.
Chronology and procedural posture
- Complaint filed: January 30, 2025, in the District of Delaware.
- Response: Azurity filed a motion to dismiss on March 15, 2025, citing patent invalidity.
- Claims construction: The court scheduled a Markman hearing for July 20, 2025, to interpret key patent claim terms.
- Summary judgment: The parties agreed to early discovery on validity issues, with a tentative trial date set for March 2026.
Patent validity defenses
- Obviousness: Azurity argues the patent claims are invalid under 35 U.S.C. § 103 due to prior art references, including a 2015 publication that discloses similar methods.
- Lack of inventive step: They assert there was no unexpected technical advantage over prior methods.
- Prior public use: Azurity claims the methods were publicly used by third parties before the patent filing.
Infringement allegations
- Exelixis asserts Azurity's marketed product is used according to the patented method, especially in the dosage and administration schedule.
- Azurity contends their generic product uses a different formulation and delivery method that does not infringe.
Court proceedings and legal strategies
- The court's Markman ruling will determine the scope of patent claims, critical for infringement and validity analysis.
- Exelixis’s strategy hinges on establishing patent validity through evidence of non-obviousness and unexpected results.
- Azurity aims to invalidate the patent by emphasizing prior art and differences in drug formulation.
Market and financial implications
- Approval of Azurity’s generic could significantly impact Exelixis’s revenues, which were approximately $1.2 billion in 2024.
- A favorable ruling for Azurity could lead to a rapid market entrance, reducing Exelixis’s market share for cabozantinib.
Key legal issues
- Validity of patent claims based on prior art and obviousness.
- Whether Azurity's product infringes the patent claims.
- Scope of the patent claims as interpreted in the Markman hearing.
- Potential settlement or licensing negotiations pending trial.
Industry and competitive landscape
- Exelixis’s patent protections are critical, with patent expiration looming in 2030.
- The case exemplifies the ongoing patent battles in oncology therapeutics, especially around generics.
Key dates and deadlines
| Event |
Date |
| Complaint filing |
January 30, 2025 |
| Motion to dismiss |
March 15, 2025 |
| Markman hearing |
July 20, 2025 |
| Fact discovery completion |
December 15, 2025 |
| Summary judgment motions |
February 15, 2026 |
| Trial date |
March 2026 |
Summary analysis
This case centers on the validity of Exelixis’s patent in the face of obviousness challenges from Azurity. Success for Exelixis depends on demonstrating the patent’s claims cover non-obvious, innovative methods with unexpected advantages. Azurity’s defenses focus on prior art evidence and differences in formulation that do not infringe. The outcome hinges on the court’s interpretation of patent claims, the strength of prior art evidence, and expert testimonies.
Key takeaways
- The case reflects typical dynamics in pharmaceutical patent litigation involving innovators and generic challengers.
- Validity defenses such as obviousness are contested heavily in similar biotech disputes.
- A decision favoring Azurity could accelerate generic entry, impacting Exelixis’s market share.
- The case demonstrates the importance of patent claim construction in infringement and validity determinations.
- Ongoing patent reforms and litigation strategies influence the biotech sector’s innovation landscape.
FAQs
Q1: What is the significance of the Markman hearing in this case?
It defines the meanings of key patent terms, impacting infringement and validity analyses.
Q2: Can Azurity's argument about prior art invalidate the patent?
Yes, if the court finds the prior art renders the claims obvious under 35 U.S.C. § 103.
Q3: How could a patent invalidation affect Exelixis?
It could allow Azurity to market a generic version earlier, reducing Exelixis’s revenue.
Q4: What is a typical time frame for patent litigation in biotech?
Two to three years from filing to trial, depending on complexity and procedural motions.
Q5: How does this case compare to other biotech patent disputes?
It shares common issues of obviousness challenges and the importance of patent claim scope.
Citations
[1] U.S. Patent No. 10,789,032. (2022). "Methods of Treating Cancer with Cabozantinib."
[2] District of Delaware. (2025). Complaint in Exelixis, Inc. v. Azurity Pharmaceuticals, Inc. | 1:25-cv-00478.
